Industry, advocates and legislators are in agreement that there must be changes to the federal 340B Drug Discount Program to control its growth, but it remains unclear which direction Congress will go to solve the issue.
Ted Alexander, a senior legislative assistant for House Energy & Commerce Health Subcommittee member Rep. Chris Collins (R-N.Y.), acknowledged that...







